Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan

Journal of Headache and Pain

Volumn 9, Issue 6, 2008, Pages 359-365

  Diener, Cans Christoph ^a   Dowson, Andrew ^b   Whicker, Susan ^c   Bacon, Teresa ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c GlaxoSmithKline Consumer Healthcare ^*  (Australia)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Migraine; Naratriptan; Non prescription medicine; Pharmacy questionnaire; Sumatriptan

Indexed keywords

NARATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ACCURACY; ADULT; ARTICLE; AUSTRALIA; CHRONIC DAILY HEADACHE; CLINICAL ASSESSMENT; CLUSTER HEADACHE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE QUESTIONNAIRE; PATIENT SELECTION; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; TENSION HEADACHE; UNITED KINGDOM; VALIDATION PROCESS;

ADULT; COMMUNITY PHARMACY SERVICES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PHARMACISTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TRYPTAMINES; YOUNG ADULT;

EID: 56549091419     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-008-0070-6     Document Type: Article

References (14)

1. World Health Organization (2004) Headache disorders. Fact Sheet No. 277, March 2004. Accessed 29 June 2008
2. MacGregor EA, Brandes J, Eikermann A (2003) Migraine prevalence and treatment patterns: The global Migraine and Zolmitriptan Evaluation survey. Headache 43:19-26
3. Lipton RB, Stewart WF, Scher AI (2001) Epidemiology and economic impact of migraine. Curr Med Res Opin 17(suppl 1):s4-s12
4. American Association for the Study of Headache, International Headache Society (1998) Consensus statement on improving migraine management. Headache 38:736
5. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet; 358:1668-1675
6. Tfelt-Hansen P, Steiner TJ (2007) Over-the-counter triptans for migraine: What are the implications? CNS Drugs 21:877-883
7. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W (2003) A self-administered screener for migraine in primary care: The ID Migraine (TM) validation study. Neurology 61:375-382
8. Dowson AJ, Turner A, Kilminster S, Glover C, Lipscombe S (2005) Development and validation of the Headache Diagnostic Screening Questionnaire (DSQ): A new questionnaire for the differential diagnosis of headache for use in primary care. Headache Care 2:111-118
9. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23:519-527
10. Diener HC, Kaube H, Limmroth V (1998) A practical guide to the management and prevention of migraine. Drugs 58:811-824
11. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S (2003) Coprescription of triptans with potentially interacting medications: A cohort study involving 240268 patients. Headache 43:44-48
12. Shapiro RE, Tepper SJ (2007) The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 47:266-269
13. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J (2004) Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44:414-425
14. Headache Classification Subcommittee of International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):1-160